Identifying Patients at Risk for Life-threatening Adverse Effect of Chemotherapy
A genetic biomarker may help identify breast cancer patients at increased risk for heart damage caused by anthracycline chemotherapy.
Progress Against Cancer
A genetic biomarker may help identify breast cancer patients at increased risk for heart damage caused by anthracycline chemotherapy.
Researchers are using genetic tests to help identify breast cancer patients at risk for potentially life-threatening complications of chemotherapy. Blood clots that develop in the veins of patients – known as venous thromboembolism or...
The U.S. FDA decision to approve nivolumab for head and neck cancer means nivolumab is now an approved treatment for five types of cancer.
A recent study reports that how pediatricians talk to parents can affect whether or not they chose to have their child vaccinated against human papillomavirus (HPV). For pediatricians and parents of adolescents, across the...
Each of the three obesity-related factors, body mass index (BMI), waist size, and type 2 diabetes, was associated with liver cancer risk in a large study.
An investigational immunotherapeutic was safe, tolerable, and showed some activity against melanoma in a phase I clinical trial.
The FDA approved a molecularly targeted therapeutic for treating certain patients with soft tissue sarcoma.
The number of Hispanic breast cancer patients in California getting care and participating in a clinical trial increased, a study found.
The lack of androgen receptor protein may contribute to racial disparities in survival for women with this aggressive form of breast cancer.
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with lung cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More